Boston Children’s Hospital, Dana-Farber Cancer Institute, and Broad Clinical Labs have joined forces to establish BrightSeq, a clinical research consortium delivering integrated tissue and liquid biopsy genomic profiling for pediatric cancer patients. This collaboration aims to enhance diagnostic precision and prognostic evaluations for rare childhood cancers. The initiative represents a significant developmental milestone for pediatric oncology, enabling tailored, comprehensive genomic insights to inform clinical decisions.